Conference Coverage
Videos
NewsNetwork
OncLive® TV
Peer Exchange
Insights
Attend An Event
State of the Science Summit
Regional Seminar Series
PER Conferences
Giants of Cancer Care
ISGIO
Webinars
OncLive Community
SPECIALTY TOPICS
CURRENTLY VIEWING
All Specialties
Breast Cancer
Multiple Myeloma
Lung Cancer
Immuno-Oncology News
Gynecologic Oncology
Gastrointestinal Cancer
Colorectal Cancer
Ovarian Cancer
Prostate Cancer
Precision Medicine in Oncology®
Neoadjuvant HER2+
More >>
Related Articles
KTE-X19 Shows High CR Rates for MCL, FDA Submission Planned
Acalabrutinib Benefit in CLL Sustained With Long-Term Follow-Up
Liso-Cel Continues to Show Promise in Relapsed/Refractory CLL/SLL
Related Videos
Dr. Smith on the Rationale Behind the Fixed Duration Trial for Ibrutinib/Venetoclax in CLL
Dr. Lampson on Safety and Efficacy of Acalabrutinib, Venetoclax, and Obinutuzumab in CLL
Dr. Seymour on the 4-Year Update of the MURANO Trial in CLL
OncologyLive > Vol. 20/No. 21 >

Taking CLL Therapies From Bedside to Community

Tony Berberabe, MPH @OncBiz_Wiz
Published: Sunday, Nov 03, 2019
Michael J. Keating, MBB, Department of Leukemia at The University of Texas MD Anderson Cancer Center in Houston

Michael J. Keating, MBB

"I am an addict."
... to read the full story
To Read the Full Story
REGISTER
LOG IN

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
 
x